This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Das Verbundprojekt „Personalisierte Medizin für die Onkologie“ (PM4Onco) als Teil der Medizininformatik-Initiative (MII)
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz Open Access 13 May 2024
-
Molecular diagnostics of hepatobiliary and pancreatic neoplasias
Virchows Archiv Open Access 01 February 2024
-
The role of molecular tumor boards in neuro-oncology: a nationwide survey
BMC Cancer Open Access 19 January 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fioretos, T. et al. Nat. Med. 28, 1980–1982 (2022).
Taskén, K. et al. Nat. Med. 28, 885–887 (2022).
Renovanz, M. et al. Neuroncol. Adv. https://doi.org/10.1093/noajnl/vdad012 (2023).
Joos, S. et al. Mol. Oncol. 13, 535–542 (2019).
Horak, P. et al. Cancer Discov. 11, 2780–2795 (2021).
Saiyed, M. M., Ong, P. S. & Chew, L. J. Clin. Pharm. Ther. 42, 251–258 (2017).
Schett, G., McInnes, I. B. & Neurath, M. F. N. Engl. J. Med. 385, 628–639 (2021).
Stenzinger, A. et al. Semin Cancer Biol. 84, 242–254 (2022).
Vicente, A. M., Ballensiefen, W. & Jönsson, J. I. J. Transl. Med. 18, 180 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.L.I. received honoraria for consulting and advisory boards from Janssen-Cilag, AbbVie, Roche, AstraZeneca, Amgen and Takeda. A.S. has received honoraria for consulting and/or advisory boards from Agilent, Aignostics, Amgen, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, Roche, Seagen, Takeda, and Thermo Fisher; and grants from Bayer, BMS, Chugai, and Incyte. M.B. received honoraria for advisory boards from Roche, Incyte Biosciences Germany, Bayer Vital, BMS, MSD Sharp & Dome, Taiho Oncology Europe, and EISAI. V.I.G. is on the advisory board for Jazz Pharmaceuticals and Abbvie; received speakers bureau fees for Pfizer, Janssen, and Abbvie; and travel support from Abbvie. S.L. reports research grant from BMS, advisory board/speaker invitation from AstraZeneca, Eli Lily, Roche, and Takeda outside of this work. S.O. received honoraria for workshop presentations at conferences from Illumina. M.H. received honoraria for lectures, presentations, speakers bureaus and consulting advisory boards from Abbvie, Roche, AstraZeneca, Gilead, Janssen, and Beigene. P.A. received fees from Ferring Pharmaceuticals and Bayer. T.F. received honoraria from Onkowissen. P.B. received honoraria for consulting and advisory boards from Bristol Myers Squibb, AstraZeneca, Amgen, and MSD. D.S. has been on the advisory board, an invited speaker, or committee member for BMS, Immunocore, Merck Serono, MSD, Neracare, Novartis, Pfizer, Philogen, Pierre Fabre, Roche, Sanofi, and Regeneron; received research grants from or been principal investigator for BMS, MSD, Novartis, Philogen, Pierre Fabre, and Sanofi; and is a member of the board of directors for EORTC-MG. A.B. received honoraria for consulting and advisory boards from MSD, Boehringer Ingelheim, Takeda, AstraZeneca, BMS, Lilly, Roche Pharma, Pfizer, Sanofi, Janssen-Cilag, Bayer Vital, Amgen, Novartis, and Daiichi Sankyo. C.H.B. received honoraria for consulting and advisory boards from MSD, BMS and Novartis. I.E. received consulting fees from Incyte Bioscience International. E.M. received speaker honoraria from Roche and Boehringer Ingelheim; and is on an advisory board for Roche. C.B. has been on the advisory board, an invited speaker, or committee member for AOK Germany, AstraZeneca, Bayer Healthcare, BioNTech, Bristol Myers Squipp, Jansen Cilag, Med Update, Merck Serono, Oncology Drug Consult CRO, Roche Pharma, and Sanofi Aventis; several clinical trials sponsored by industry; member of board of directors for DGHO and Northern German Society of Internal Medicine; leadership roles at Hamburg Cancer Society and National Network of German Cancer Centers (DKH); and advisory role at board of DGHO advisors. S.F. received consulting fees or advisory board membership from Bayer, Illumina, and Roche; honoraria from Amgen, Eli Lilly, PharmaMar, and Roche; research funding from AstraZeneca, Pfizer, PharmaMar, and Roche; and travel or accommodation expenses from Amgen, Eli Lilly, Illumina, PharmaMar, and Roche. H.A. received honoraria for consulting and advisory boards from AstraZeneca, Viatris, Pfizer, and Servier. V.H. declares honoraria for talks and advisory board roles from Merck, Amgen, Roche, Sanofi, SIRTEX, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS, MSD, Novartis, Boehringer Ingelheim, Celgene, Terumo, Oncosil, Seagen, and NORDIC Pharma; and research funding from Merck, Amgen, Roche, Sanofi, Pfizer, Boehringer Ingelheim, SIRTEX, and Servier. R.B. is patent holder for blinatumomab, from which he receives royalty payments, and has consulted for and received honoraria from Amgen, Cellex, and Gemoab. P.H. received honoraria from MSD and AstraZeneca. F.L. received honoraria from Astellas, AstraZeneca, BMS, MSD, and Roche. A.H. received research support from Novartis, BMS, Pfizer, and Incyte. M.T. received honoraria for consulting or advisory boards from Janssen-Cilag, Roche, AstraZeneca, Amgen, Takeda, BMS, IO Medico, Sana, RKH Kliniken, ConEvent, Med Update, VHS Stadtbergen, I-Med Institut, and Klinikum Esslingen. J.B. received honoraria from MSD. M.W. reports research grant from BMS outside of this work. A.J.B. received honoraria for talks, consulting, or advisory boards from Siemens Healthineers, NVision, and AAA/Novartis. G.T. has served on advisory boards for Bayer, Boehringer Ingelheim, CureVac, and Novocure, consulted for Bayer, Boehringer Ingelheim, and CureVac; was a steering committee member in non-interventional trials for Bayer and Novocure; with financial compensation for all these activities provided as institutional funding to the University Hospital Tübingen. W.W. received research grants from Roche, MSD, BMS, and AstraZeneca; advisory board, lectures, speaker bureaus fees from Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Janssen, Amgen, Astellas, Illumina, Eisai, Siemens, Agilent, ADC, GSK, and Molecular Health. U.K. received research support from AstraZeneca; and honoraria from BMS, MSD, Merck, and Novartis. T.S. received honoraria for consulting of editorial boards for Servier, M&D, BMS, Mirati, Olympus Fondation Pierre Fabre, and Eli Lilly. P.S. received honoraria from speakers bureau or advisory boards for Incyte, BMS, Eisai, MSD, AstraZeneca, and Amgen; and from BMS, Gilead, Incyte, and Huygai. All other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Illert, A.L., Stenzinger, A., Bitzer, M. et al. The German Network for Personalized Medicine to enhance patient care and translational research. Nat Med 29, 1298–1301 (2023). https://doi.org/10.1038/s41591-023-02354-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02354-z
This article is cited by
-
The role of molecular tumor boards in neuro-oncology: a nationwide survey
BMC Cancer (2024)
-
Registerbasierte Krebsforschung in Deutschland
Forum (2024)
-
Molecular diagnostics of hepatobiliary and pancreatic neoplasias
Virchows Archiv (2024)
-
Sondersituation der Daten in der Onkologie
Die Onkologie (2024)
-
Einsatz von Arzneimitteln außerhalb der Zulassung – Conditio sine qua non in der Präzisionsonkologie?
Forum (2024)